A CD123-Specific Chimeric Antigen Receptor Augments Anti-Acute Myeloid Leukemia Activity of Vγ9Vδ2 T Cells

0301 basic medicine Receptors, Chimeric Antigen T-Lymphocytes Interleukin-3 Receptor alpha Subunit Mice, SCID Immunotherapy, Adoptive Xenograft Model Antitumor Assays 3. Good health Leukemia, Myeloid, Acute Mice 03 medical and health sciences Mice, Inbred NOD Cell Line, Tumor Animals Humans
DOI: 10.2217/imt-2021-0143 Publication Date: 2022-02-14T09:54:06Z
ABSTRACT
Aim: To investigate whether anti-CD123 chimeric antigen receptor (CAR)-expressing Vγ9Vδ2 T cells could be an alternative for acute myeloid leukemia (AML) treatment. Materials & methods:Ex vivo expanded were electroporated with CAR-encoding mRNA. The effector function and specificity of the modified examined by in vitro cytotoxicity, degranulation cytokine release level. was analyzed using xenograft KG1-luc model NOD-SCID-γc-/- mice. Results: exhibited significantly improved activities against both AML cell lines primary vitro. In mouse model, displayed enhanced tumor control potency. Conclusion: Anti-CD123 CAR-expressing may serve as way to target AML.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (46)
CITATIONS (7)